The Newswire

Your daily serving of financial goodness

ALS Posts $174.5m Full Year Loss

ALS Posts $174.5m Full Year Loss
May 28, 2015 By Simon Herrmann

Laboratory services company ALS Limited (ASX:ALQ) announced a fall in revenue and profits in its FY2015 Results announcement on Thursday. Revenue for the full-year ending on 31 March 2015 fell 0.7 per cent to $1,492.7m compared to the previous corresponding period (PCP). Net profit after tax (NPAT) fell 213 per cent, from a gain $154.4m in the PCP to a loss of $174.5m. Basic earnings per share fell 84.1c to negative 43.4c per share. Total dividends for the year fell 46.2 per cent to 21c per share.

ALS said the primary cause for the profit loss was due to the $290.6m impairment charge on its oil and gas investments. The company said it was unprepared to deal with the rapidly falling global oil prices global. "Markets for our services remain challenging in an environment of falling commodity prices and a strong cost focus from most clients," said chairman Nerolie Withnall. The company was conducting a strategic consolidation to move into specialist oil and gas technical services. Between September 2014 and March 2015, the company saw oil prices fall 40 per cent. The integration of its new strategic consolidation was unprepared for the collapsing oil prices, and thus was impaired at a loss for ALS.

ALS provides geochemical and metallurgical testing services and mine site services, in addition to certifications for the coal, oil and gas industries. Like many other Australian businesses, the down turn in mining and commodity-focused industries has been extended to ALS. The final yearly dividend for the company has been cut in half to 10c per share, 2.5c franked. The interim dividend has been nearly cut in half to 11c per share, 9.9c franked. Shares of ALQ have fallen 43c, or 6.69 per cent, at $6.00 per share near the end of trading on Thursday. ALQ has fallen 29.65 per cent in the last 12 months but has risen 12.66 per cent so far this year.

 

Share this article

Simon Herrmann Author: Simon Herrmann May 28, 2015

Simon is a financial analyst at independent research firm Wise-owl who wants to change the world by disrupting the cliché approach to investment decision making with convergent thinking. Wise-owl’s goal is plain and simple: Find the best opportunities for our members by following a proven methodology and to create long-term value through high-quality advice, innovation, technology and education. We combine industry experience and the agile mentality of a start-up. Wise-owl is the future of stock market investing.

Growing Cases of Cancer Fuel Demand for Diagnostic Technology: Sienna Cancer IPO

The Australian government estimates that over 130,000 new cancer cases will be diagnosed in 2017 and the risk of individuals dying from cancer by their 85th birthday will be one in five.

Author: Simon Herrmann Jun 23, 2017

Errors

Sign Up for Free Trial
Subscribe
Recent Tweets
Recent News